Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up to $15.36

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $15.36, but opened at $16.27. Day One Biopharmaceuticals shares last traded at $15.39, with a volume of 333,419 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, June 19th. JPMorgan Chase & Co. upped their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday, April 22nd. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Friday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Day One Biopharmaceuticals Price Performance

The firm’s 50-day simple moving average is $14.00 and its 200-day simple moving average is $14.83. The firm has a market capitalization of $1.34 billion, a PE ratio of -6.25 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). On average, equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.69 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total transaction of $320,200.00. Following the completion of the sale, the insider now directly owns 1,121,081 shares in the company, valued at $17,948,506.81. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Jeremy Bender sold 70,051 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total value of $1,252,511.88. Following the completion of the transaction, the chief executive officer now directly owns 651,762 shares of the company’s stock, valued at $11,653,504.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total transaction of $320,200.00. Following the completion of the transaction, the insider now directly owns 1,121,081 shares of the company’s stock, valued at $17,948,506.81. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 195,534 shares of company stock worth $3,367,830. Company insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently bought and sold shares of DAWN. Quest Partners LLC bought a new position in Day One Biopharmaceuticals in the fourth quarter worth about $29,000. Quintet Private Bank Europe S.A. boosted its holdings in Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Day One Biopharmaceuticals in the second quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 352.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after purchasing an additional 7,841 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Day One Biopharmaceuticals in the fourth quarter worth approximately $156,000. 87.95% of the stock is owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.